The American Journal of Medicine
Volume 123, Issue 1 , Pages 87.e1-87.e6 , January 2010

Care of the Cancer Survivor: Metabolic Syndrome after Hormone-Modifying Therapy

  • Amanda J. Redig, PhD

      Affiliations

    • Feinberg School of Medicine, Northwestern University, Chicago, Ill
    • Division of Hematology/Oncology, Department of Medicine and the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Ill
    • Corresponding Author InformationReprint requests should be addressed to Amanda J. Redig, PhD, Robert H. Lurie Comprehensive Cancer Center, 303 East Superior Street, Lurie 3-220, Chicago, IL 60611
    • ,
  • Hidayatullah G. Munshi, MD

      Affiliations

    • Division of Hematology/Oncology, Department of Medicine and the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Ill
    • The Jesse Brown VA Medical Center, Chicago, Ill

References 

  1. Joslin E. The prevention of diabetes mellitus. JAMA. 1921;76:79–84
  2. Reaven GM. Banting Lecture 1988 (Role of insulin resistance in human disease. 1988). Nutrition. 1997;13:65;discussion 64, 66
  3. Fraze E, Donner CC, Swislocki AL, et al. Ambient plasma free fatty acid concentrations in noninsulin-dependent diabetes mellitus: evidence for insulin resistance. J Clin Endocrinol Metab. 1985;61:807–811
  4. Ferrannini E, Natali A, Cerri M, et al. Hypertension: a metabolic disorder?. Diabetes Metab. 1989;15:284–291
  5. Foster DW. Insulin resistance—a secret killer?. N Engl J Med. 1989;320:733–734
  6. Haller H. [Epidermiology and associated risk factors of hyperlipoproteinemia]. Z Gesamte Inn Med. 1977;32:124–128
  7. Pagano G, Cassader M. Insulin resistance in spontaneous obesity (Role of insulin receptors). Minerva Dietol Gastroenterol. 1979;25:265–274
  8. Karam JH. Type II diabetes and syndrome X (Pathogenesis and glycemic management). Endocrinol Metab Clin North Am. 1992;21:329–350
  9. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the Third National Health and Nutrition Examination Survey. JAMA. 2002;287:356–359
  10. Park YW, Zhu S, Palaniappan L, et al. The metabolic syndrome: prevalence and associated risk factor findings in the US population from the Third National Health and Nutrition Examination Survey, 1988-1994. Arch Intern Med. 2003;163:427–436
  11. Pothiwala P, Jain SK, Yaturu S. Metabolic syndrome and cancer. Metab Syndr Relat Disord. 2009;7:279–288
  12. Keating NL, O'Malley AJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol. 2006;24:4448–4456
  13. Cuppone F, Bria E, Verma S, et al. Do adjuvant aromatase inhibitors increase the cardiovascular risk in postmenopausal women with early breast cancer? (Meta-analysis of randomized trials). Cancer. 2008;112:260–267
  14. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001;285:2486–2497
  15. Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 2005;112:2735–2752
  16. Solymoss BC, Bourassa MG, Marcil M, et al. Long-term rates of cardiovascular events in patients with the metabolic syndrome according to severity of coronary-angiographic alterations. Coron Artery Dis. 2009;20:1–8
  17. Boppidi H, Daram SR. Nonalcoholic fatty liver disease: hepatic manifestation of obesity and the metabolic syndrome. Postgrad Med. 2008;120:E01–E07
  18. Castaneda E, Perez AE, Guillen MA, et al. Metabolic studies in a patient with testicular feminization syndrome. Am J Obstet Gynecol. 1971;110:1002–1007
  19. Wortsman J, Soler NG. Abnormalities of fuel metabolism in the polycystic ovary syndrome. Obstet Gynecol. 1982;60:342–345
  20. Cupisti S, Kajaia N, Dittrich R, et al. Body mass index and ovarian function are associated with endocrine and metabolic abnormalities in women with hyperandrogenic syndrome. Eur J Endocrinol. 2008;158:711–719
  21. Regitz-Zagrosek V, Lehmkuhl E, Weickert MO. Gender differences in the metabolic syndrome and their role for cardiovascular disease. Clin Res Cardiol. 2006;95:136–147
  22. Dunaif A, Thomas A. Current concepts in the polycystic ovary syndrome. Annu Rev Med. 2001;52:401–419
  23. Dunaif A. Insulin resistance in women with polycystic ovary syndrome. Fertil Steril. 2006;86(suppl 1):S13–S14
  24. Stanworth RD, Jones TH. Testosterone in obesity, metabolic syndrome and type 2 diabetes. Front Horm Res. 2009;37:74–90
  25. Lunenfeld B. Testosterone deficiency and the metabolic syndrome. Aging Male. 2007;10:53–56
  26. D'Amico AV, Renshaw AA, Loffredo B, Chen MH. Duration of testosterone suppression and the risk of death from prostate cancer in men treated using radiation and 6 months of hormone therapy. Cancer. 2007;110:1723–1728
  27. Denham JW, Steigler A, Lamb DS, et al. Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial. Lancet Oncol. 2005;6:841–850
  28. Tsai HK, D'Amico AV, Sadetsky N, et al. Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality. J Natl Cancer Inst. 2007;99:1516–1524
  29. Saigal CS, Gore JL, Krupski TL, et al. Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer. Cancer. 2007;110:1493–1500
  30. Braga-Basaria M, Dobs AS, Muller DC, et al. Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy. J Clin Oncol. 2006;24:3979–3983
  31. Traish AM, Saad F, Feeley RJ, Guay AT. The dark side of testosterone deficiency: III (Cardiovascular disease). J Androl. 2009;30:477–494Epub 2009 Apr 2
  32. Lage MJ, Barber BL, Markus RA. Association between androgen-deprivation therapy and incidence of diabetes among males with prostate cancer. Urology. 2007;70:1104–1108
  33. Basaria S, Muller DC, Carducci MA, et al. Hyperglycemia and insulin resistance in men with prostate carcinoma who receive androgen-deprivation therapy. Cancer. 2006;106:581–588
  34. Traish AM, Saad F, Guay A. The dark side of testosterone deficiency: II (Type 2 diabetes and insulin resistance). J Androl. 2009;30:23–32
  35. Smith MR, Lee H, Fallon MA, Nathan DM. Adipocytokines, obesity, and insulin resistance during combined androgen blockade for prostate cancer. Urology. 2008;71:318–322
  36. Derweesh IH, Diblasio CJ, Kincade MC, et al. Risk of new-onset diabetes mellitus and worsening glycaemic variables for established diabetes in men undergoing androgen-deprivation therapy for prostate cancer. BJU Int. 2007;100:1060–1065
  37. Vuppalanchi R, Chalasani N. Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: selected practical issues in their evaluation and management. Hepatology. 2009;49:306–317
  38. Gabbi C, Carubbi F, Losi L, et al. Nonalcoholic fatty liver disease induced by leuprorelin acetate. J Clin Gastroenterol. 2008;42:107–110
  39. Herrington DM, Klein KP. Cardiovascular trials of estrogen replacement therapy. Ann N Y Acad Sci. 2001;949:153–162
  40. Love RR, Wiebe DA, Newcomb PA, et al. Effects of tamoxifen on cardiovascular risk factors in postmenopausal women. Ann Intern Med. 1991;115:860–864
  41. Dewar JA, Horobin JM, Preece PE, et al. Long term effects of tamoxifen on blood lipid values in breast cancer. BMJ. 1992;305:225–226
  42. Saarto T, Blomqvist C, Ehnholm C, et al. Effects of chemotherapy-induced castration on serum lipids and apoproteins in premenopausal women with node-positive breast cancer. J Clin Endocrinol Metab. 1996;81:4453–4457
  43. McDonald CC, Alexander FE, Whyte BW, et al. Cardiac and vascular morbidity in women receiving adjuvant tamoxifen for breast cancer in a randomised trial (The Scottish Cancer Trials Breast Group). BMJ. 1995;311:977–980
  44. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365:1687–1717
  45. Buzdar A, Howell A, Cuzick J, et al. Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial. Lancet Oncol. 2006;7:633–643
  46. Coates AS, Keshaviah A, Thurlimann B, et al. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. J Clin Oncol. 2007;25:486–492
  47. Mouridsen H, Keshaviah A, Coates AS, et al. Cardiovascular adverse events during adjuvant endocrine therapy for early breast cancer using letrozole or tamoxifen: safety analysis of BIG 1-98 trial. J Clin Oncol. 2007;25:5715–5722
  48. Thurlimann B, Keshaviah A, Coates AS, et al. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med. 2005;353:2747–2757
  49. Rock CL, Flatt SW, Newman V, et al. Factors associated with weight gain in women after diagnosis of breast cancer (Women's Healthy Eating and Living Study Group). J Am Diet Assoc. 1999;99:1212–1221
  50. Irwin ML, Crumley D, McTiernan A, et al. Physical activity levels before and after a diagnosis of breast carcinoma: the Health, Eating, Activity, and Lifestyle (HEAL) study. Cancer. 2003;97:1746–1757
  51. Chlebowski RT, Aiello E, McTiernan A. Weight loss in breast cancer patient management. J Clin Oncol. 2002;20:1128–1143
  52. Ahmed MH, Saad RA, Osman MM. Ezetimibe: effective and safe treatment for dyslipidaemia associated with nonalcoholic fatty liver disease (Response to: Toth PP, Davidson MH: simvastatin and ezetimibe: combination therapy for the management of dyslipidaemia). Expert Opin Pharmacother. 2005;6:131–139Expert Opin Drug Saf. 2006;5:487-488
  53. Nguyen MC, Stewart RB, Banerji MA, et al. Relationships between tamoxifen use, liver fat and body fat distribution in women with breast cancer. Int J Obes Relat Metab Disord. 2001;25:296–298
  54. Bruno S, Maisonneuve P, Castellana P, et al. Incidence and risk factors for non-alcoholic steatohepatitis: prospective study of 5408 women enrolled in Italian tamoxifen chemoprevention trial. BMJ. 2005;330:932
  55. Dorum A, Tonstad S, Liavaag AH, et al. Bilateral oophorectomy before 50 years of age is significantly associated with the metabolic syndrome and Framingham risk score: a controlled, population-based study (HUNT-2). Gynecol Oncol. 2008;109:377–383
  56. Michelsen TM, Pripp AH, Tonstad S, et al. Metabolic syndrome after risk-reducing salpingo-oophorectomy in women at high risk for hereditary breast ovarian cancer: a controlled observational study. Eur J Cancer. 2009;45:82–89
  57. Cuzick J, Ambroisine L, Davidson N, et al. Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: a meta-analysis of individual patient data from randomised adjuvant trials. Lancet. 2007;369:1711–1723
  58. Cohen P. Metformin for the prevention of androgen deprivation induced metabolic syndrome, obesity and type 2 diabetes. Med Hypotheses. 2009;72:227–228
  59. Goodwin PJ. Insulin in the adjuvant breast cancer setting: a novel therapeutic target for lifestyle and pharmacologic interventions?. J Clin Oncol. 2008;26:833–834
  60. Hede K. Doctors seek to prevent breast cancer recurrence by lowering insulin levels. J Natl Cancer Inst. 2008;100:530–532
  61. Mathur R, Alexander CJ, Yano J, et al. Use of metformin in polycystic ovary syndrome. Am J Obstet Gynecol. 2008;199:596–609
  62. Galvao DA, Newton RU, Taaffe DR, Spry N. Can exercise ameliorate the increased risk of cardiovascular disease and diabetes associated with ADT?. Nat Clin Pract Urol. 2008;5:306–307
  63. Martin CK, Church TS, Thompson AM, et al. Exercise dose and quality of life: a randomized controlled trial. Arch Intern Med. 2009;169:269–278
  64. Ligibel JA, Campbell N, Partridge A, et al. Impact of a mixed strength and endurance exercise intervention on insulin levels in breast cancer survivors. J Clin Oncol. 2008;26:907–912
  65. D'Amico AV, Denham JW, Bolla M, et al. Short- vs long-term androgen suppression plus external beam radiation therapy and survival in men of advanced age with node-negative high-risk adenocarcinoma of the prostate. Cancer. 2007;109:2004–2010

 Funding: This work was supported by a National Institutes of Health predoctoral fellowship F30ES015668 (to A.J.R.) and grant R01CA126888 from the National Cancer Institute and a Merit grant award from the Department of Veterans Affairs (to H.G.M.).

 Conflict of Interest: Neither author has any conflicts of interest associated with the work presented in this manuscript.

 Authorship: Both authors had access to the data and played a role in writing this manuscript.

PII: S0002-9343(09)00685-8

doi: 10.1016/j.amjmed.2009.06.022

The American Journal of Medicine
Volume 123, Issue 1 , Pages 87.e1-87.e6 , January 2010

Article Tools